Drug intelligence / Profile preview

OCN19-overexpressed human umbilical cord-derived mesenchymal stem cells

Development stage: Phase 2
Lead developer: Changhai Hospital
Modality: Gene Therapies, Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

OCN19-overexpressed human umbilical cord-derived mesenchymal stem cells is an investigational cell and gene therapy designed to treat refractory type 2 diabetes mellitus. This therapeutic product consists of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) that have been genetically modified to overexpress OCN19, a protein variant or fragment of osteocalcin. The mechanism of action is dual-fold: the MSCs provide well-documented immunomodulatory and tissue-regenerative effects, while the overexpressed OCN19 specifically targets the pancreatic environment to directly stimulate insulin gene expression and promote the division and proliferation of islet beta cells. By enhancing endogenous insulin production and repairing islet function, this therapy aims to achieve superior glycemic control compared to standard stem cell treatments. It is currently being evaluated in Phase 2 clinical trials.

Other names: OCN19-overexpressed hUC-MSCsOCN-19-overexpressed hUC-MSCsOCN 19-overexpressed hUC-MSCsOCN19-modified human umbilical cord-derived mesenchymal stem cellsOCN-19-modified human umbilical cord-derived mesenchymal stem cellsOCN 19-modified human umbilical cord-derived mesenchymal stem cells

Beyond the preview

Go deeper on OCN19-overexpressed human umbilical cord-derived mesenchymal stem cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OCN19-overexpressed human umbilical cord-derived mesenchymal stem cells.

Explore the full profile